Having compliance problems with insulin?

Having compliance problems with insulin?

By NZMS Diabetes
2 minutes to Read
Hosted content - diabetes device
Removing treatment barriers and burden helps to set patients up for success in a way that meets their lifestyle, helping them achieve their treatment , injection versus pump image
References
  1. https://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-illnesses/diabetes
  2. Meneghini L. Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. Int J Clin Pract 2008;62(8):1255-64.
  3. Hayes R, Fitzgerald J, Jacober S. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J of Clin Pract 2008;62(6):860-8.
  4. New Zealand Guidelines Group (NZGG). Guidance on the management of type 2 diabetes. NZGG, 2011. Available from: www.nzgg.org.nz/practice-tools/diabetes (Accessed Dec, 2011)
  5. Instructions for Patient Use. Valeritas; 2011.
  6. Carls GS, Tuttle E, Tan RD, et al. Understanding the gap between efficacy in randomised controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care. 2017;40:1469-1478.
  7. Bohannon N, Kelman A, Leichter S, et al. Patient perceptions of the V-Go insulin delivery device. ADA 69th Scientific Sessions; June 5-9, 2009; New Orleans, LA. PO-1993.
Mandatories

Important Risk Information: Always read the label and use only as directed. If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at mealtimes requires adjustments of less than 2-Unit increments, use of the V-Go Insulin Patch Pump may result in hypoglycaemia. The following conditions may occur during insulin therapy with V-Go: hypoglycaemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use may include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing. A healthcare professional should be consulted to see if this product is right for the patient. V-Go is a registered trademark of Valeritas, Inc.© 2018 Valeritas, Inc. Distributed in New Zealand by NZMS Diabetes, 2a Fisher Crescent, Mt Wellington, Auckland.